Want to see VCEL full AI Analyst Report?
Top Page
Vericel
(NASDAQ:VCEL)
Select Model
Select Model
Rating:74Outperform
Price Target:
$52.00
▲(15.43% Upside)
Action:Reiterated
Date:07/30/26
The score is driven primarily by improving financial performance (shift to sustained profitability and strong TTM cash generation) and supportive technical trend (price above rising key moving averages). The latest earnings call adds upside via raised 2026 guidance and strong quarterly execution, while the overall score is held back by expensive valuation (very high P/E) and the identified risks around moderating growth, cash-flow variability, and BARDA revenue timing.
Positive Factors
Margin expansion & sustained profitability
Vericel has moved from multi-year losses to sustainable profitability with materially expanded gross and net margins. Higher gross margins reflect scalable manufacturing and pricing power in autologous therapies, supporting durable cash flow and reinvestment capacity.
Negative Factors
Dependence on biopsy-to-implant conversion
Revenue growth for MACI hinges on maintaining biopsy-to-implant conversion rates across expanding territories. Conversion is operational and behavioral, sensitive to surgeon habits and payer access; a sustained drop would directly compress volumes and undermine long-term revenue momentum.
Read all positive and negative factors
Positive Factors
Negative Factors
Margin expansion & sustained profitability
Vericel has moved from multi-year losses to sustainable profitability with materially expanded gross and net margins. Higher gross margins reflect scalable manufacturing and pricing power in autologous therapies, supporting durable cash flow and reinvestment capacity.
Read all positive factors
Vericel (VCEL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.39B
Dividend YieldN/A
Average Volume (3M)626.39K
Price to Earnings (P/E)108.9
Beta (1Y)0.91
Revenue Growth22.45%
EPS Growth602.15%
CountryUS
Employees398
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.48
Shares Outstanding51,068,230
10 Day Avg. Volume486,320
30 Day Avg. Volume626,386
Financial Highlights & Ratios
PEG Ratio1.91
Price to Book (P/B)5.14
Price to Sales (P/S)6.59
P/FCF Ratio73.61
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$59.25Price Target Upside31.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.47
Revenue Forecast (FY)$332.18M
Vericel Business Overview & Revenue Model
Company Description
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medic...
How the Company Makes Money
Vericel primarily makes money by selling its FDA-approved commercial products to healthcare providers (e.g., hospitals, burn centers, and orthopedic/sports-medicine providers) and recognizing revenue when product is delivered/provided and the rela...
Vericel Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Positive
The call conveyed a strongly positive operational and financial quarter: record revenue, double-digit MACI growth, materially improved margins, robust cash generation, successful sales force expansion, regulatory and manufacturing milestones, and a meaningful BARDA award. The key near-term risks are timing and contingent nature of BARDA-related revenue, the need to sustain biopsy-to-implant conversion, modest near-term margin variability due to investments, and external macro/access uncertainties. On balance, the positives substantially outweigh the challenges.Positive Updates
Record Quarterly Revenue and Strong YoY Growth
Total revenue of $68.4M in Q1 2026, up 30% year-over-year and significantly above company guidance.
Negative Updates
BARDA-Related Revenue Timing and Uncertainty
While BARDA award is sizable (up to $197M), only a portion is contracted now (base $35M) and optional awards/ramps (additional procurement, blast-indication development, room-temperature formulation) are contingent and will materialize over multiple years; expected H2 2026 procurement revenue is modest (~$5M–$6M).
Read all updates
Q1-2026 Updates
Positive
Negative
Record Quarterly Revenue and Strong YoY Growth
Total revenue of $68.4M in Q1 2026, up 30% year-over-year and significantly above company guidance.
Read all positive updates
Company Guidance
Vericel raised full-year 2026 guidance by $10 million to $326–$336 million in total revenue (≈20% growth at the midpoint), driven by a strong Q1 beat (Q1 revenue $68.4M, +30% YoY), MACI strength and expected NexoBrid BARDA procurement; MACI guidance was nudged to $282–$288M with Q2 MACI expected at ~$62.5–$63.5M (MACI Q1 $56.4M, +22%, trailing-4Q growth 23%), Burn Care guidance was raised to ~$44–$48M (Q1 Burn Care $12M, +90%+, Q2 Burn Care ~$9–$10M), and management expects ~$5–$6M of NexoBrid BARDA procurement revenue in H2 (procurement to begin in Q3) from a BARDA award up to $197M (base $35M); profitability/cash targets were reiterated with full-year gross margin ~75% (Q2 ~72%), full-year adjusted EBITDA margin ~27% (Q2 ~18%), Q1 gross margin 72% (+300 bps), adjusted EBITDA nearly $10M (Q1 adjusted EBITDA margin 14%, up ~800 bps; adj. EBITDA +195% YoY), operating cash flow $16.4M and free cash flow $15.1M (third consecutive quarter ≥$12M) and ~$211M in cash and investments at quarter end.Vericel Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 306.30M | 276.26M | 237.22M | 197.52M | 164.37M | 156.18M |
| Gross Profit | 228.38M | 205.60M | 172.11M | 135.58M | 109.79M | 106.03M |
| EBITDA | 30.00M | 30.29M | 16.63M | 2.86M | -11.64M | -4.61M |
| Net Income | 24.22M | 16.52M | 10.36M | -3.18M | -16.71M | -7.47M |
Balance Sheet | ||||||
| Total Assets | 502.87M | 487.97M | 432.72M | 353.66M | 273.00M | 243.71M |
| Cash, Cash Equivalents and Short-Term Investments | 162.46M | 137.50M | 116.21M | 109.56M | 119.54M | 103.40M |
| Total Debt | 92.54M | 98.27M | 98.85M | 88.04M | 47.57M | 50.18M |
| Total Liabilities | 132.82M | 133.33M | 140.75M | 127.70M | 80.73M | 73.24M |
| Stockholders Equity | 370.04M | 354.64M | 291.97M | 225.95M | 192.27M | 170.46M |
Cash Flow | ||||||
| Free Cash Flow | 49.64M | 24.75M | -5.81M | 7.80M | 10.09M | 21.13M |
| Operating Cash Flow | 69.67M | 51.91M | 58.16M | 35.31M | 17.69M | 29.04M |
| Investing Cash Flow | -26.79M | -43.94M | -79.03M | -3.13M | -36.21M | -3.50M |
| Financing Cash Flow | 1.94M | 7.07M | 19.05M | 3.62M | 1.04M | 9.17M |
Vericel Technical Analysis
Positive
45.05
Price Trends
41.14
Positive
37.40
Positive
37.25
Positive
Market Momentum
1.35
Positive
53.86
Neutral
15.21
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VCEL, the sentiment is Positive. The current price of 45.05 is below the 20-day moving average (MA) of 46.40, above the 50-day MA of 41.14, and above the 200-day MA of 37.25, indicating a bullish trend. The MACD of 1.35 indicates Positive momentum. The RSI at 53.86 is Neutral, neither overbought nor oversold. The STOCH value of 15.21 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VCEL.
Vericel Risk Analysis
Vericel disclosed 66 risk factors in its most recent earnings report. Vericel reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vericel Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $1.92B | 6.68 | 64.48% | ― | 20.62% | 696.05% | |
74 Outperform | $2.39B | 108.88 | 6.41% | ― | 22.45% | 602.15% | |
62 Neutral | $4.34B | -24.31 | -32.55% | ― | ― | -7.28% | |
58 Neutral | $2.48B | -5.63 | 123.57% | ― | 75.92% | -569.22% | |
56 Neutral | $2.79B | -8.33 | -50.72% | ― | -88.54% | -58.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $1.26B | -21.62 | -38.11% | ― | 18.24% | -5.21% |
* Healthcare Sector Average
VCEL
Vericel
46.62
5.96
14.66%
BCRX
BioCryst
9.53
1.31
15.94%
CLDX
Celldex
37.51
14.70
64.45%
ARDX
Ardelyx
5.00
0.66
15.21%
AUPH
Aurinia Pharmaceuticals
15.18
6.13
67.73%
EWTX
Edgewise Therapeutics
39.75
25.52
179.34%
Vericel Corporate Events
Executive/Board ChangesShareholder Meetings
Vericel Shareholders Reaffirm Board, Pay Plan, Auditor
Positive
May 1, 2026
At Vericel Corporation’s April 29, 2026 annual shareholders’ meeting, investors re-elected seven directors, including CEO Dominick Colangelo, to one-year terms ending at the 2027 meeting, signaling continued support for the companyR...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.